Literature DB >> 19556606

Attenuation of chronic pulmonary inflammation in A2B adenosine receptor knockout mice.

Rinat Zaynagetdinov1, Sergey Ryzhov, Anna E Goldstein, Huiyong Yin, Sergey V Novitskiy, Kasia Goleniewska, Vasiliy V Polosukhin, Dawn C Newcomb, Daphne Mitchell, Eva Morschl, Yang Zhou, Michael R Blackburn, R Stokes Peebles, Italo Biaggioni, Igor Feoktistov.   

Abstract

Pharmacologic evidence suggests that activation of A(2B) adenosine receptors results in proinflammatory effects relevant to the progression of asthma, a chronic lung disease associated with elevated interstitial adenosine concentrations in the lung. This concept has been challenged by the finding that genetic removal of A(2B) receptors leads to exaggerated responses in models of acute inflammation. Therefore, the goal of our study was to determine the effects of A(2B) receptor gene ablation in the context of ovalbumin-induced chronic pulmonary inflammation. We found that repetitive airway allergen challenge induced a significant increase in adenosine levels in fluid recovered by bronchoalveolar lavage. Genetic ablation of A(2B) receptors significantly attenuated allergen-induced chronic pulmonary inflammation, as evidenced by a reduction in the number of bronchoalveolar lavage eosinophils and in peribronchial eosinophilic infiltration. The most striking difference in the pulmonary inflammation induced in A(2B) receptor knockout (A(2B)KO) and wild-type mice was the lack of allergen-induced IL-4 release in the airways of A(2B)KO animals, in line with a significant reduction in IL-4 protein and mRNA levels in lung tissue. In addition, attenuation of allergen-induced transforming growth factor-beta release in airways of A(2B)KO mice correlated with reduced airway smooth muscle and goblet cell hyperplasia/hypertrophy. In conclusion, genetic removal of A(2B) adenosine receptors in mice leads to inhibition of allergen-induced chronic pulmonary inflammation and airway remodeling. These findings are in agreement with previous pharmacologic studies suggesting a deleterious role for A(2B) receptor signaling in chronic lung inflammation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19556606      PMCID: PMC2874442          DOI: 10.1165/rcmb.2008-0391OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  41 in total

1.  High adenosine plasma concentration as a prognostic index for outcome in patients with septic shock.

Authors:  C Martin; M Leone; X Viviand; M L Ayem; R Guieu
Journal:  Crit Care Med       Date:  2000-09       Impact factor: 7.598

2.  Eosinophil major basic protein-1 does not contribute to allergen-induced airway pathologies in mouse models of asthma.

Authors:  K L Denzler; S C Farmer; J R Crosby; M Borchers; G Cieslewicz; K A Larson; S Cormier-Regard; N A Lee; J J Lee
Journal:  J Immunol       Date:  2000-11-15       Impact factor: 5.422

3.  Role of adenosine receptors in the regulation of angiogenic factors and neovascularization in hypoxia.

Authors:  Sergey Ryzhov; Jennifer L McCaleb; Anna E Goldstein; Italo Biaggioni; Igor Feoktistov
Journal:  J Pharmacol Exp Ther       Date:  2006-11-28       Impact factor: 4.030

4.  Mast cell-mediated stimulation of angiogenesis: cooperative interaction between A2B and A3 adenosine receptors.

Authors:  Igor Feoktistov; Sergey Ryzhov; Anna E Goldstein; Italo Biaggioni
Journal:  Circ Res       Date:  2003-02-13       Impact factor: 17.367

Review 5.  Too much of a good thing: adenosine overload in adenosine-deaminase-deficient mice.

Authors:  Michael R Blackburn
Journal:  Trends Pharmacol Sci       Date:  2003-02       Impact factor: 14.819

6.  A2B adenosine receptor gene deletion attenuates murine colitis.

Authors:  Vasantha L Kolachala; Matam Vijay-Kumar; Guillaiume Dalmasso; Dan Yang; Joel Linden; Lixin Wang; Andrew Gewirtz; Katya Ravid; Didier Merlin; Shanthi V Sitaraman
Journal:  Gastroenterology       Date:  2008-05-21       Impact factor: 22.682

7.  Adenosine receptors in regulation of dendritic cell differentiation and function.

Authors:  Sergey V Novitskiy; Sergey Ryzhov; Rinat Zaynagetdinov; Anna E Goldstein; Yuhui Huang; Oleg Y Tikhomirov; Michael R Blackburn; Italo Biaggioni; David P Carbone; Igor Feoktistov; Mikhail M Dikov
Journal:  Blood       Date:  2008-06-17       Impact factor: 22.113

8.  Adenosine in exhaled breath condensate in healthy volunteers and in patients with asthma.

Authors:  E Huszár; G Vass; E Vizi; Zs Csoma; E Barát; Gy Molnár Világos; I Herjavecz; I Horváth
Journal:  Eur Respir J       Date:  2002-12       Impact factor: 16.671

Review 9.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors.

Authors:  B B Fredholm; A P IJzerman; K A Jacobson; K N Klotz; J Linden
Journal:  Pharmacol Rev       Date:  2001-12       Impact factor: 18.923

10.  Metabolic consequences of adenosine deaminase deficiency in mice are associated with defects in alveogenesis, pulmonary inflammation, and airway obstruction.

Authors:  M R Blackburn; J B Volmer; J L Thrasher; H Zhong; J R Crosby; J J Lee; R E Kellems
Journal:  J Exp Med       Date:  2000-07-17       Impact factor: 14.307

View more
  28 in total

1.  Anti-inflammatory or proinflammatory effect of an adenosine receptor agonist on the Th17 autoimmune response is inflammatory environment-dependent.

Authors:  Dongchun Liang; Aijun Zuo; Hui Shao; Mingjiazi Chen; Henry J Kaplan; Deming Sun
Journal:  J Immunol       Date:  2014-11-03       Impact factor: 5.422

2.  The A2B adenosine receptor modulates pulmonary hypertension associated with interstitial lung disease.

Authors:  Harry Karmouty-Quintana; Hongyan Zhong; Luis Acero; Tingting Weng; Ernestina Melicoff; James D West; Anna Hemnes; Almut Grenz; Holger K Eltzschig; Timothy S Blackwell; Yang Xia; Richard A Johnston; Dewan Zeng; Luiz Belardinelli; Michael R Blackburn
Journal:  FASEB J       Date:  2012-03-13       Impact factor: 5.191

3.  A(₂B)AR expression in non-immune cells plays an important role in the development of murine colitis.

Authors:  Sarah A Ingersoll; Hamed Laroui; Vasantha L Kolachala; Lixin Wang; Pallavi Garg; Timothy L Denning; Andrew T Gewirtz; Didier Merlin; Shanthi V Sitaraman
Journal:  Dig Liver Dis       Date:  2012-06-19       Impact factor: 4.088

Review 4.  Beneficial and detrimental role of adenosine signaling in diseases and therapy.

Authors:  Hong Liu; Yang Xia
Journal:  J Appl Physiol (1985)       Date:  2015-08-27

Review 5.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

6.  Sustained adenosine exposure causes lung endothelial barrier dysfunction via nucleoside transporter-mediated signaling.

Authors:  Qing Lu; Julie Newton; Vivian Hsiao; Paul Shamirian; Michael R Blackburn; Mesias Pedroza
Journal:  Am J Respir Cell Mol Biol       Date:  2012-06-28       Impact factor: 6.914

Review 7.  Adverse and protective influences of adenosine on the newborn and embryo: implications for preterm white matter injury and embryo protection.

Authors:  Scott A Rivkees; Christopher C Wendler
Journal:  Pediatr Res       Date:  2011-04       Impact factor: 3.756

Review 8.  The Many Faces of the A2b Adenosine Receptor in Cardiovascular and Metabolic Diseases.

Authors:  Anna Eisenstein; Shenia Patterson; Katya Ravid
Journal:  J Cell Physiol       Date:  2015-12       Impact factor: 6.384

9.  Response of Differentiated Human Airway Epithelia to Alcohol Exposure and Klebsiella Pneumoniae Challenge.

Authors:  Sammeta V Raju; Richard G Painter; Gregory J Bagby; Steve Nelson; Guoshun Wang
Journal:  Med Sci (Basel)       Date:  2013-07-26

10.  Alterations in adenosine metabolism and signaling in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.

Authors:  Yang Zhou; Jayasimha N Murthy; Dewan Zeng; Luiz Belardinelli; Michael R Blackburn
Journal:  PLoS One       Date:  2010-02-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.